SG11201608566UA - New markers for the assessment of an increased risk for mortality - Google Patents

New markers for the assessment of an increased risk for mortality

Info

Publication number
SG11201608566UA
SG11201608566UA SG11201608566UA SG11201608566UA SG11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA SG 11201608566U A SG11201608566U A SG 11201608566UA
Authority
SG
Singapore
Prior art keywords
mortality
assessment
increased risk
new markers
markers
Prior art date
Application number
SG11201608566UA
Other languages
English (en)
Inventor
Sybille Hess
Hertzel Gerstein
Guillaume Pare
Matthew Mcqueen
Original Assignee
Sanofi Aventis Deutschland
Univ Mcmaster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland, Univ Mcmaster filed Critical Sanofi Aventis Deutschland
Publication of SG11201608566UA publication Critical patent/SG11201608566UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201608566UA 2014-06-05 2015-06-03 New markers for the assessment of an increased risk for mortality SG11201608566UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305856 2014-06-05
EP14306530 2014-09-30
PCT/EP2015/062460 WO2015185672A2 (en) 2014-06-05 2015-06-03 New markers for the assessment of an increased risk for mortality

Publications (1)

Publication Number Publication Date
SG11201608566UA true SG11201608566UA (en) 2016-11-29

Family

ID=53385620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608566UA SG11201608566UA (en) 2014-06-05 2015-06-03 New markers for the assessment of an increased risk for mortality

Country Status (7)

Country Link
US (1) US20170102396A1 (de)
EP (2) EP3152580B1 (de)
CN (1) CN107076756B (de)
CA (1) CA2949731A1 (de)
IL (1) IL249322A0 (de)
SG (1) SG11201608566UA (de)
WO (1) WO2015185672A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110161252B (zh) * 2014-03-21 2022-10-14 赛诺菲-安万特德国有限公司 用于评估心血管病症进展风险的新标志物
JP6622102B2 (ja) * 2016-02-04 2019-12-18 松森　昭 急性心筋梗塞の判定方法
SG11202002391PA (en) * 2017-10-24 2020-04-29 Sphingotec Gmbh Selenoprotein p for prediction of a first cardiovascular event
BR112020011454A2 (pt) * 2017-12-13 2021-02-09 F. Hoffmann-La Roche Ag métodos para prever o risco de acidente vascular, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão e usos do (i) biomarcador ang-2 e/ou do biomarcador igfbp7
CN113631926A (zh) * 2018-12-20 2021-11-09 思芬构技术有限公司 心力衰竭中的硒蛋白p
CN112180093B (zh) * 2019-07-02 2024-03-08 复旦大学附属华山医院 危重病死亡率诊断性生物标志物tenascin-c及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092911A1 (en) * 2005-10-03 2007-04-26 Buechler Kenneth F Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes
EP2310860A1 (de) * 2008-07-30 2011-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Blutglutathion als biomarker zur untersuchung asymptomatischer herzinfarkt-gefährdeter patienten
WO2010029116A1 (en) * 2008-09-11 2010-03-18 F. Hoffmann-La Roche Ag Natriuretic peptides and adiponectin in subjects with a metabolic syndrome
EA201290711A1 (ru) * 2010-02-26 2013-10-30 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
WO2012094580A2 (en) * 2011-01-07 2012-07-12 High Point Pharmaceuticals, Llc Compounds that modulate oxidative stress
KR102111624B1 (ko) * 2011-09-30 2020-05-18 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
WO2013152047A1 (en) * 2012-04-02 2013-10-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
US9733261B2 (en) * 2012-04-24 2017-08-15 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
US20140072959A1 (en) * 2012-09-12 2014-03-13 Force Diagnostics, Inc. Rapid tests for insurance underwriting

Also Published As

Publication number Publication date
CN107076756A (zh) 2017-08-18
CN107076756B (zh) 2019-08-16
EP3633382A1 (de) 2020-04-08
WO2015185672A3 (en) 2016-02-25
CA2949731A1 (en) 2015-12-10
WO2015185672A2 (en) 2015-12-10
EP3152580A2 (de) 2017-04-12
EP3152580B1 (de) 2019-10-16
IL249322A0 (en) 2017-02-28
US20170102396A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
GB2512543B (en) Object tracking
PT3034453T (pt) Equipamento com trasladador lateral
SG11201610690VA (en) Ethylene-based polymers
GB201407680D0 (en) Indicator
IL246499A0 (en) Rebalancing the immune system in skin care
GB2528233B (en) Identifying features
IL249322A0 (en) New markers for testing the increased risk of mortality
HK1242947A1 (zh) 彈簧彈出的活檢標記物
GB201417553D0 (en) Embryo Assessment
SG11201606346TA (en) Intermittent-bubbling equipment
IL247366A0 (en) Inhibitors of wnt signaling pathways
GB2533151B (en) Improved probe
PT3151658T (pt) Ferradura
GB201504086D0 (en) Life jacket attachment
GB201409620D0 (en) Range determination
GB201518601D0 (en) Equipment calibration
SG11201701736TA (en) Thermal-history-change-type indicator
GB201401005D0 (en) Inhibitor
SG11201702732UA (en) Oxidant-dependent time indicator
GB201414306D0 (en) Test target
GB201417275D0 (en) Tripod Portion
TWM490643U (en) Transformer
GB201406771D0 (en) Assessment system
GB201712443D0 (en) Markers
GB201619771D0 (en) Indicator